Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

Timely diagnosis of intraepithelial neoplasias (IN) and colitis-associated colon carcinomas (CRC) is crucially important for the treatment of ulcerative colitis (UC).

The researchers performed a randomized, controlled trial to test whether chromoendoscopy (CE) might facilitate early detection of IN and CRC in UC.

Who Took Part

According to the abstract, 263 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults.

Five mucosal biopsy specimens were taken every 10 cm between the rectum and cecum.

How the Study Was Run

In design terms this was a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Methylene blue (non-peptide stack partner) study would be practical.

Circumscript lesions in the colon were evaluated according to a modified pit pattern classification.

What Was Measured

The subject headings attached to it are Biopsy, Carcinoma in Situ, Colitis, Ulcerative, Colonic Neoplasms, Colonoscopy, Coloring Agents and Methylene Blue.

What This Means in Plain Language

The paper is a randomized and pilot study of Methylene blue (non-peptide stack partner) in 263 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Gastroenterology), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.